Global Meningococcal Vaccines Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Meningococcal vaccines Market, by Market Value (US$ Mn) and Volume(Ton)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global Meningococcal vaccines Market Analysis and Forecast
6.1. Global Meningococcal vaccines Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Meningococcal vaccines Market Analysis and Forecast, by Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Meningococcal vaccines Market Value Share Analysis, by Type
7.4. Global Meningococcal vaccines Market Size (US$ Mn) Forecast, by Type
7.5. Global Meningococcal vaccines Market Analysis, by Type
7.6. Global Meningococcal vaccines Market Attractiveness Analysis, by Type
8. Global Meningococcal vaccines Market Analysis and Forecast, by End Users
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Meningococcal vaccines Market Value Share Analysis, by End Users
8.4. Global Meningococcal vaccines Market Size (US$ Mn) Forecast, by End Users
8.5. Global Meningococcal vaccines Market Analysis, by End Users
8.6. Global Meningococcal vaccines Market Attractiveness Analysis, by End Users
9. Global Meningococcal vaccines Market Analysis, by Region
9.1. Global Meningococcal vaccines Market Value Share Analysis, by Region
9.2. Global Meningococcal vaccines Market Size (US$ Mn) Forecast, by Region
9.3. Global Meningococcal vaccines Market Attractiveness Analysis, by Region
10. North America Meningococcal vaccines Market Analysis
10.1. Key Findings
10.2. North America Meningococcal vaccines Market Overview
10.3. North America Meningococcal vaccines Market Value Share Analysis, by Type
10.4. North America Meningococcal vaccines Market Forecast, by Type
10.4.1. Quadrivalent vaccines
10.4.2. Bivalent vaccines
10.4.3. Serogroup A
10.4.4. Serogroup B
10.4.5. Serogroup X
10.5. North America Meningococcal vaccines Market Value Share Analysis, by End Users
10.6. North America Meningococcal vaccines Market Forecast, by End Users
10.6.1. Children
10.6.2. Preteens or Teens
10.6.3. Adults
10.7. North America Meningococcal vaccines Market Value Share Analysis, by Country
10.8. North America Meningococcal vaccines Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.9. North America Meningococcal vaccines Market Analysis, by Country
10.10. U.S. Meningococcal vaccines Market Forecast, by Type
10.10.1. Quadrivalent vaccines
10.10.2. Bivalent vaccines
10.10.3. Serogroup A
10.10.4. Serogroup B
10.10.5. Serogroup X
10.11. U.S. Meningococcal vaccines Market Forecast, by End Users
10.11.1. Children
10.11.2. Preteens or Teens
10.11.3. Adults
10.12. Canada Meningococcal vaccines Market Forecast, by Type
10.12.1. Quadrivalent vaccines
10.12.2. Bivalent vaccines
10.12.3. Serogroup A
10.12.4. Serogroup B
10.12.5. Serogroup X
10.13. Canada Meningococcal vaccines Market Forecast, by End Users
10.13.1. Children
10.13.2. Preteens or Teens
10.13.3. Adults
10.14. North America Meningococcal vaccines Market Attractiveness Analysis
10.14.1. By Type
10.14.2. By End Users
10.15. PEST Analysis
10.16. Key Trends
10.17. Key Development
11. Europe Meningococcal vaccines Market Analysis
11.1. Key Findings
11.2. Europe Meningococcal vaccines Market Overview
11.3. Europe Meningococcal vaccines Market Value Share Analysis, by Type
11.4. Europe Meningococcal vaccines Market Forecast, by Type
11.4.1. Quadrivalent vaccines
11.4.2. Bivalent vaccines
11.4.3. Serogroup A
11.4.4. Serogroup B
11.4.5. Serogroup X
11.5. Europe Meningococcal vaccines Market Value Share Analysis, by End Users
11.6. Europe Meningococcal vaccines Market Forecast, by End Users
11.6.1. Children
11.6.2. Preteens or Teens
11.6.3. Adults
11.7. Europe Meningococcal vaccines Market Value Share Analysis, by Country
11.8. Europe Meningococcal vaccines Market Forecast, by Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Europe Meningococcal vaccines Market Analysis, by Country
11.10. Germany Meningococcal vaccines Market Forecast, by Type
11.10.1. Quadrivalent vaccines
11.10.2. Bivalent vaccines
11.10.3. Serogroup A
11.10.4. Serogroup B
11.10.5. Serogroup X
11.11. Germany Meningococcal vaccines Market Forecast, by End Users
11.11.1. Children
11.11.2. Preteens or Teens
11.11.3. Adults
11.12. U.K. Meningococcal vaccines Market Forecast, by Type
11.12.1. Quadrivalent vaccines
11.12.2. Bivalent vaccines
11.12.3. Serogroup A
11.12.4. Serogroup B
11.12.5. Serogroup X
11.13. U.K. Meningococcal vaccines Market Forecast, by End Users
11.13.1. Children
11.13.2. Preteens or Teens
11.13.3. Adults
11.14. France Meningococcal vaccines Market Forecast, by Type
11.14.1. Quadrivalent vaccines
11.14.2. Bivalent vaccines
11.14.3. Serogroup A
11.14.4. Serogroup B
11.14.5. Serogroup X
11.15. France Meningococcal vaccines Market Forecast, by End Users
11.15.1. Children
11.15.2. Preteens or Teens
11.15.3. Adults
11.16. Italy Meningococcal vaccines Market Forecast, by Type
11.16.1. Quadrivalent vaccines
11.16.2. Bivalent vaccines
11.16.3. Serogroup A
11.16.4. Serogroup B
11.16.5. Serogroup X
11.17. Italy Meningococcal vaccines Market Forecast, by End Users
11.17.1. Children
11.17.2. Preteens or Teens
11.17.3. Adults
11.18. Spain Meningococcal vaccines Market Forecast, by Type
11.18.1. Quadrivalent vaccines
11.18.2. Bivalent vaccines
11.18.3. Serogroup A
11.18.4. Serogroup B
11.18.5. Serogroup X
11.19. Spain Meningococcal vaccines Market Forecast, by End Users
11.19.1. Children
11.19.2. Preteens or Teens
11.19.3. Adults
11.20. Rest of Europe Meningococcal vaccines Market Forecast, by Type
11.20.1. Quadrivalent vaccines
11.20.2. Bivalent vaccines
11.20.3. Serogroup A
11.20.4. Serogroup B
11.20.5. Serogroup X
11.21. Rest of Europe Meningococcal vaccines Market Forecast, by End Users
11.21.1. Children
11.21.2. Preteens or Teens
11.21.3. Adults
11.22. Europe Meningococcal vaccines Market Attractiveness Analysis
11.22.1. By Type
11.22.2. By End Users
11.23. PEST Analysis
11.24. Key Trends
11.25. Key Development
12. Asia Pacific Meningococcal vaccines Market Analysis
12.1. Key Findings
12.2. Asia Pacific Meningococcal vaccines Market Overview
12.3. Asia Pacific Meningococcal vaccines Market Value Share Analysis, by Type
12.4. Asia Pacific Meningococcal vaccines Market Forecast, by Type
12.4.1. Quadrivalent vaccines
12.4.2. Bivalent vaccines
12.4.3. Serogroup A
12.4.4. Serogroup B
12.4.5. Serogroup X
12.5. Asia Pacific Meningococcal vaccines Market Value Share Analysis, by End Users
12.6. Asia Pacific Meningococcal vaccines Market Forecast, by End Users
12.6.1. Children
12.6.2. Preteens or Teens
12.6.3. Adults
12.7. Asia Pacific Meningococcal vaccines Market Value Share Analysis, by Country
12.8. Asia Pacific Meningococcal vaccines Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. ASEAN
12.8.5. Rest of Asia Pacific
12.9. Asia Pacific Meningococcal vaccines Market Analysis, by Country
12.10. China Meningococcal vaccines Market Forecast, by Type
12.10.1. Quadrivalent vaccines
12.10.2. Bivalent vaccines
12.10.3. Serogroup A
12.10.4. Serogroup B
12.10.5. Serogroup X
12.11. China Meningococcal vaccines Market Forecast, by End Users
12.11.1. Children
12.11.2. Preteens or Teens
12.11.3. Adults
12.12. India Meningococcal vaccines Market Forecast, by Type
12.12.1. Quadrivalent vaccines
12.12.2. Bivalent vaccines
12.12.3. Serogroup A
12.12.4. Serogroup B
12.12.5. Serogroup X
12.13. India Meningococcal vaccines Market Forecast, by End Users
12.13.1. Children
12.13.2. Preteens or Teens
12.13.3. Adults
12.14. Japan Meningococcal vaccines Market Forecast, by Type
12.14.1. Quadrivalent vaccines
12.14.2. Bivalent vaccines
12.14.3. Serogroup A
12.14.4. Serogroup B
12.14.5. Serogroup X
12.15. Japan Meningococcal vaccines Market Forecast, by End Users
12.15.1. Children
12.15.2. Preteens or Teens
12.15.3. Adults
12.16. ASEAN Meningococcal vaccines Market Forecast, by Type
12.16.1. Quadrivalent vaccines
12.16.2. Bivalent vaccines
12.16.3. Serogroup A
12.16.4. Serogroup B
12.16.5. Serogroup X
12.17. ASEAN Meningococcal vaccines Market Forecast, by End Users
12.17.1. Children
12.17.2. Preteens or Teens
12.17.3. Adults
12.18. Rest of Asia Pacific Meningococcal vaccines Market Forecast, by Type
12.18.1. Quadrivalent vaccines
12.18.2. Bivalent vaccines
12.18.3. Serogroup A
12.18.4. Serogroup B
12.18.5. Serogroup X
12.19. Rest of Asia Pacific Meningococcal vaccines Market Forecast, by End Users
12.19.1. Children
12.19.2. Preteens or Teens
12.19.3. Adults
12.20. Asia Pacific Meningococcal vaccines Market Attractiveness Analysis
12.20.1. By Type
12.20.2. By End Users
12.21. PEST Analysis
12.22. Key Trends
12.23. Key Development
13. Middle East & Africa Meningococcal vaccines Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Meningococcal vaccines Market Overview
13.3. Middle East & Africa Meningococcal vaccines Market Value Share Analysis, by Type
13.4. Middle East & Africa Meningococcal vaccines Market Forecast, by Type
13.4.1. Quadrivalent vaccines
13.4.2. Bivalent vaccines
13.4.3. Serogroup A
13.4.4. Serogroup B
13.4.5. Serogroup X
13.5. Middle East & Africa Meningococcal vaccines Market Value Share Analysis, by End Users
13.6. Middle East & Africa Meningococcal vaccines Market Forecast, by End Users
13.6.1. Children
13.6.2. Preteens or Teens
13.6.3. Adults
13.7. Middle East & Africa Meningococcal vaccines Market Value Share Analysis, by Country
13.8. Middle East & Africa Meningococcal vaccines Market Forecast, by Country
13.8.1. GCC
13.8.2. South Africa
13.8.3. Rest of Middle East & Africa
13.9. Middle East & Africa Meningococcal vaccines Market Analysis, by Country
13.10. GCC Meningococcal vaccines Market Forecast, by Type
13.10.1. Quadrivalent vaccines
13.10.2. Bivalent vaccines
13.10.3. Serogroup A
13.10.4. Serogroup B
13.10.5. Serogroup X
13.11. GCC Meningococcal vaccines Market Forecast, by End Users
13.11.1. Children
13.11.2. Preteens or Teens
13.11.3. Adults
13.12. South Africa Meningococcal vaccines Market Forecast, by Type
13.12.1. Quadrivalent vaccines
13.12.2. Bivalent vaccines
13.12.3. Serogroup A
13.12.4. Serogroup B
13.12.5. Serogroup X
13.13. South Africa Meningococcal vaccines Market Forecast, by End Users
13.13.1. Children
13.13.2. Preteens or Teens
13.13.3. Adults
13.14. Rest of Middle East & Africa Meningococcal vaccines Market Forecast, by Type
13.14.1. Quadrivalent vaccines
13.14.2. Bivalent vaccines
13.14.3. Serogroup A
13.14.4. Serogroup B
13.14.5. Serogroup X
13.15. Rest of Middle East & Africa Meningococcal vaccines Market Forecast, by End Users
13.15.1. Children
13.15.2. Preteens or Teens
13.15.3. Adults
13.16. Middle East & Africa Meningococcal vaccines Market Attractiveness Analysis
13.16.1. By Type
13.16.2. By End Users
13.17. PEST Analysis
13.18. Key Trends
13.19. Key Development
14. South America Meningococcal vaccines Market Analysis
14.1. Key Findings
14.2. South America Meningococcal vaccines Market Overview
14.3. South America Meningococcal vaccines Market Value Share Analysis, by Type
14.4. South America Meningococcal vaccines Market Forecast, by Type
14.4.1. Quadrivalent vaccines
14.4.2. Bivalent vaccines
14.4.3. Serogroup A
14.4.4. Serogroup B
14.4.5. Serogroup X
14.5. South America Meningococcal vaccines Market Value Share Analysis, by End Users
14.6. South America Meningococcal vaccines Market Forecast, by End Users
14.6.1. Children
14.6.2. Preteens or Teens
14.6.3. Adults
14.7. South America Meningococcal vaccines Market Value Share Analysis, by Country
14.8. South America Meningococcal vaccines Market Forecast, by Country
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of South America
14.9. South America Meningococcal vaccines Market Analysis, by Country
14.10. Brazil Meningococcal vaccines Market Forecast, by Type
14.10.1. Quadrivalent vaccines
14.10.2. Bivalent vaccines
14.10.3. Serogroup A
14.10.4. Serogroup B
14.10.5. Serogroup X
14.11. Brazil Meningococcal vaccines Market Forecast, by End Users
14.11.1. Children
14.11.2. Preteens or Teens
14.11.3. Adults
14.12. Mexico Meningococcal vaccines Market Forecast, by Type
14.12.1. Quadrivalent vaccines
14.12.2. Bivalent vaccines
14.12.3. Serogroup A
14.12.4. Serogroup B
14.12.5. Serogroup X
14.13. Mexico Meningococcal vaccines Market Forecast, by End Users
14.13.1. Children
14.13.2. Preteens or Teens
14.13.3. Adults
14.14. Rest of South America Meningococcal vaccines Market Forecast, by Type
14.14.1. Quadrivalent vaccines
14.14.2. Bivalent vaccines
14.14.3. Serogroup A
14.14.4. Serogroup B
14.14.5. Serogroup X
14.15. Rest of South America Meningococcal vaccines Market Forecast, by End Users
14.15.1. Children
14.15.2. Preteens or Teens
14.15.3. Adults
14.16. South America Meningococcal vaccines Market Attractiveness Analysis
14.16.1. By Type
14.16.2. By End Users
14.17. PEST Analysis
14.18. Key Trends
14.19. Key Development
15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Applications
15.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
15.3. Company Profiles: Key Players
15.3.1. Neuron Biotech
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Company Footprint
15.3.2. Baxter international
15.3.3. Pfizer Inc.
15.3.4. Novartis International
15.3.5. Sanofi S.A.
15.3.6. JN-International Medical Corporation
15.3.7. Biomed Pvt. Ltd.
15.3.8. Serum Institute of India Ltd.
15.3.9. GlaxoSmithKline plc.
15.3.10. Merck & Co., Inc.
15.3.11. MenQuadfi
15.3.12. Walvax Biotechnology Co., Ltd.
15.3.13. Bio-Med Pvt. Ltd.
15.3.14. Chongqing Zhifei Biological Products Co., Ltd.
15.3.15. Hualan Biological Engineering, Inc.
15.3.16. Incepta Pharmaceuticals Ltd.
16. Primary Key Insights
To know about the Research Methodology :- Request Free Sample Report